COVID-19 New Coronavirus Pneumonia currently has no specific drugs, China’s Ministry of Science and Technology and medical departments have verified several effective drugs, including Fabilave. The Japanese government is now considering donating Fabilawe to more than 30 countries around the world to help them treat patients.
Fapiravir, also known as Favipiravir, commercially known as Avigan, is an antiviral drug first developed by Toyama Chemical Industry Co., Ltd. of Japan and was first patented for compounds on August 18, 1999.
The drug was approved for use in Japan in March 2014 for antiviral therapy for influenza A and B.
Studies have shown that, in addition to influenza viruses, the drug also shows good antiviral effects on a variety of RNA viruses, such as Ebola virus, sand grain virus, Bunia virus, rabies virus and so on.
In the treatment of new coronavirus pneumonia, Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, said that Fabilawi had completed clinical studies, showing good clinical efficacy, good safety, clear efficacy, medicine within easy availability, recommended promotion.
Fapilawe’s current patent period has passed, in addition to Japanese companies, there are also domestic companies to produce this drug, the current listing of Haizheng pharmaceutical favira vefilm has two specifications: the specification of 0.2g 40 tablets / box price of 780 yuan, 0.2g 20 tablets / box price of 398 yuan – the price of nearly 20 yuan per tablet.
At today’s press conference, Japan’s Chief Cabinet Secretary Yoshihide Suga said he would consider providing fapilae drugs free of charge to several countries around the world. He mentioned that more than 30 countries had requested help through diplomatic channels and that Japan would consult and expand its research.